nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.06.2012 | Original Paper

ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients

verfasst von: Marcos Antonio Mauricio Scheiner, Flavia da Cunha Vasconcelos, Roberta Rodrigues da Matta, Reinaldo Dal Bello Figueira Jr., Raquel Ciuvalschi Maia

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Polymorphisms in the ABCB1 gene may influence P-glycoprotein (Pgp) expression and/or activity. Because the population in Brazil is markedly heterogeneous, we analyzed the relationship between ABCB1 polymorphisms and Pgp expression/activity in Brazilian acute myeloid leukemia (AML) patients.

Methods

Acute myeloid leukemia samples from 109 patients were studied. ABCB1 gene variants rs1128503 (C1236T) and rs1045643 (C3435T) were analyzed by PCR-RFLP assay. Pgp expression and Pgp activity were analyzed by flow cytometry.

Results

There was a similar distribution of Pgp expression and activity on polymorphisms C1236T, C1236C, and T1236T for exon 12, and C3435T, C3435C, and T3435T for exon 26. An exception was observed in the lowest ratio of mean fluorescence intensity (MFI) median for Pgp expression in the TT genotype for both studied exons, and its correspondence to a low MFI median for Pgp activity. Pgp expression did not show impact on the response to remission induction therapy, but the MFI median of Pgp expression in the remission failure group was higher than that of the complete remission (CR) group of patients (p = 0.04). Overall survival (OS) was significantly influenced by CR (p = 0.0001). Better 5-year OS and 5-year event-free survival rates (p = 0.04 and p = 0.007, respectively) were achieved in patients presenting the genetic variant CC in exon 12 followed by those presenting the variant CT in exon 26 (p = 0.001).

Conclusions

Polymorphisms in the ABCB1 gene and the levels of Pgp expression could be useful to identify prognostic in AML patients.

Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267–3273PubMed

Buchner T, Berdel WE, Haferlach C et al (2009) Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27:61–69PubMedCrossRef

Buda G, Orciuolo E, Maggini V et al (2008) MDR1 pump: more than a drug transporter. Leuk Res 32:359–360PubMedCrossRef

Cascorbi I, Gerloff T, Johne A et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174PubMedCrossRef

Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642–4649PubMedCrossRef

Ferrara F (2010) Treatment of older patients with acute myeloid leukaemia. Lancet 376:1967–1968PubMedCrossRef

Ferrara F (2011) Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge. Clin Lymphoma Myeloma Leuk 11:10–16PubMed

Hitzl M, Drescher S, van der Kuip H (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11:293–298PubMedCrossRef

Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478PubMedCrossRef

Illmer T, Schuler US, Thiede C et al (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955–4962PubMed

Jamroziak K, Młynarski W, Balcerczak E et al (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 72:314–321PubMedCrossRef

Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93:1075–1085PubMed

Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ (2000) A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 38:1–11PubMed

Kim RB, Leake BF, Choo EF et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199PubMedCrossRef

Kim DH, Park JY, Sohn SK et al (2006) Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 118:2195–2201PubMedCrossRef

Leith CP, Kopecky KJ, Godwin J et al (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323–3329PubMed

Leith CP, Kopecky KJ, Chen IM et al (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94:1086–1099PubMed

Leschziner GD, Andrew T, Pirmohamed M, Johnson MR (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7:154–179PubMedCrossRef

Ling-Na N, Jian-Young L, Kou-Rong M et al (2011) Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28:265–269CrossRef

Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33PubMedCrossRef

Mechetner EB, Schott B, Morse SB et al (1997) P-glycoprotein function involves conformational transitions detectable differential immunoreactivity. Proc Natl Acad Sci USA 94:12908–12913PubMedCrossRef

Mizutani T, Masuda M, Nakai E (2008) Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 9:167–174PubMedCrossRef

Nagy H, Goda K, Arceci R et al (2001) P-Glycoprotein conformational changes detected by antibody competition. Eur J Biochem 268:2416–2420PubMedCrossRef

Nakamura T, Sakaeda T, Horinouchi M et al (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71:297–303PubMedCrossRef

Pauli-Magnus C, Kroetz DL (2004) Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 21:904–913PubMedCrossRef

Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA (2002) A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2:191–196PubMedCrossRef

Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW (2002) P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9:1266–1272PubMedCrossRef

Ruth A, Stein WD, Rose E, Roninson IB (2001) Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein. Biochemistry 40:4332–4339PubMedCrossRef

Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T (2005) MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 128:324–332PubMedCrossRef

Scheiner MA, Damasceno AM, Maia RC (2010) ABCB1 single nucleotide polymorphisms in the Brazilian population. Mol Biol Rep 37:111–118PubMedCrossRef

Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3–29PubMedCrossRef

Sissung TM, Baum CE, Kirkland CT et al (2010) Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 44:152–167PubMedCrossRef

Smith ML, Hills RK, Grimwade D (2011) Independent prognostic variables in acute myeloid leukemia. Blood Rev 25:39–51PubMedCrossRef

Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95:7024–7029PubMedCrossRef

Souza PS, Vasconcelos FC, Reis FRS, Morais GN, Maia RC (2011) P-glycoprotein and surviving simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol 39:925–933PubMed

Szabó K, Bakos E, Welker E et al (1997) Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity. J Biol Chem 272:23165–23171PubMedCrossRef

Tsimberidou AM, Paterakis G, Androutsos G et al (2002) Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res 26:143–154PubMedCrossRef

Van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH et al (2006) ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 80:427–439PubMedCrossRef

Van der Holt B, Breems DA, Beverloo HB et al (2007) Various distinctive cytogenetic abnormalities in patients with acute myeloid leukemia aged 60 years and older express adverse prognostic value: Results from a prospective clinical trial. Br J Haematol 136:96–105PubMedCrossRef

Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302PubMedCrossRef

Vasconcelos FC, Cavalcanti GB Jr, Silva KL et al (2007) Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res 31:445–454PubMedCrossRef

Weiss JR, Baer MR, Ambrosone CB et al (2007) Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia. Cancer Epidemiol Biomarkers Prev 16:1038–1041PubMedCrossRef

Woodahl EL, Ho RJY (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5:11–19PubMedCrossRef

Wuchter C, Leonid K, Ruppert V et al (2000) Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85:711–721PubMed

Zhou Y, Gottesman MM, Pastan I (1999) The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2. Arch Biochem Biophys 367:74–80PubMedCrossRef

Titel: ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients
verfasst von: Marcos Antonio Mauricio Scheiner
Flavia da Cunha Vasconcelos
Roberta Rodrigues da Matta
Reinaldo Dal Bello Figueira Jr.
Raquel Ciuvalschi Maia
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1170-x

Springer Medizin

ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients